Inhibition of HER2-integrin signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression

Oncotarget

Volumn 5, Issue 7, 2014, Pages 1812-1828

  Gupta, Parul ^a   Srivastava, Sanjay K ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

Breast cancer; Cucurbitacin B; In vivo; ITGA6; ITGB4

Indexed keywords

ALPHA6 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; BETA4 INTEGRIN; CUCURBITACIN; CUCURBITACIN B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ALPHA6BETA4 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; INTEGRIN-LINKED KINASE; ITGA6 PROTEIN, HUMAN; ITGB4 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR TWIST; TRITERPENE; TWIST1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; IC50; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; PHOSPHORYLATION;

ANIMALS; ANTIGENS, CD29; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHA6; INTEGRIN ALPHA6BETA4; INTEGRIN BETA3; INTEGRIN BETA4; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRITERPENES; TWIST TRANSCRIPTION FACTOR;

EID: 84899020867     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1743     Document Type: Article

References (69)

1. Siegel, R, Naishadham D and Jemal A. Cancer statistics, 20 CA: A Cancer Journal for Clinicians. 2013; 63(1):11-30.
2. Harris, L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, Jr. and American Society of Clinical O. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology. 2007; 25(33):5287-5312.
3. Slamon, DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-182.
4. King, CR, Kraus MH and Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985; 229(4717):974-976.
5. Yokota, J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H and Cline MJ. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986; 1(8484):765-767.
6. Semba, K, Kamata N, Toyoshima K and Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proceedings of the National Academy of Sciences. 1985; 82(19):6497-6501.
7. Fukushige, S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K and Yamamoto T. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Molecular and Cellular Biology. 1986; 6(3):955-958.
8. Boone, JJ, Bhosle J, Tilby MJ, Hartley JA and Hochhauser D. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Molecular Cancer Therapeutics. 2009; 8(11):3015-3023.
9. Kumar, R and Yarmand-Bagheri R. The role of HER2 in angiogenesis. Seminars in Oncology. 2001; 28(5 Suppl 16):27-32.
10. Palmieri, D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K and Steeg PS. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Research. 2007; 67(9):4190-4198.
11. Chow, A, Arteaga CL and Wang SE. When tumor suppressor TGFbeta meets the HER2 (ERBB2) oncogene. Journal of Mammary Gland Biology and Neoplasia. 2011; 16(2):81-88.
12. Osborne, CK, Shou J, Massarweh S and Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research. 2005; 11(2 Pt 2):865s-870s.
13. Wu, Y, Shang X, Sarkissyan M, Slamon D and Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Research. 2010; 70(13):5475-5485.
14. Belsches-Jablonski, AP, Biscardi JS, Peavy DR, Tice DA, Romney DA and Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene. 2001; 20(12):1465-1475.
15. Kalra, J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE and Bally MB. Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene. 2010; 29(48):6343-6356.
16. Wang, SE, Xiang B, Zent R, Quaranta V, Pozzi A and Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Srcfocal adhesion kinase and receptor association to the cytoskeleton. Cancer Research. 2009; 69(2):475-482.
17. Moja, L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V and D'Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews. 2012; 4:CD006243.
18. Desgrosellier, JS and Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer. 2010; 10(1):9-22.
19. Millard, M, Odde S and Neamati N. Integrin targeted therapeutics. Theranostics. 2011; 1:154-188.
20. Diaz, LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA and Gilcrease MZ. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Modern Pathology.2005; 18(9):1165-1175.
21. Friedrichs, K, Ruiz P, Franke F, Gille I, Terpe HJ and Imhof BA. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Research. 1995; 55(4):901-906.
22. Takayama, S, Ishii S, Ikeda T, Masamura S, Doi M and Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Research. 2005; 25(1A):79-83.
23. Liapis, H, Flath A and Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagnostic Molecular Pathology. 1996; 5(2):127-135.
24. Sloan, EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK and Anderson RL. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Research. 2006; 8(2):R20.
25. Mukhopadhyay, R, Theriault RL and Price JE. Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clinical & Experimental Metastasis. 1999; 17(4):325-332.
26. Jones, JL, Royall JE, Critchley DR and Walker RA. Modulation of myoepithelial-associated alpha6beta4 integrin in a breast cancer cell line alters invasive potential. Experimental Cell Research. 1997; 235(2):325-333.
27. Carraway, KL, 3rd and Sweeney C. Co-opted integrin signaling in ErbB2-induced mammary tumor progression. Cancer Cell. 2006; 10(2):93-95.
28. Wang, H, Leavitt L, Ramaswamy R and Rapraeger AC. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. The Journal of Biological Chemistry. 2010; 285(18):13569-13579.
29. Fan, J, Cai B, Zeng M, Hao Y, Giancotti FG and Fu BM. Integrin beta4 signaling promotes mammary tumor cell adhesion to brain microvascular endothelium by inducing ErbB2-mediated secretion of VEGF. Annals of Biomedical Engineering. 2011; 39(8):2223-2241.
30. Guo, W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G and Giancotti FG. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 2006; 126(3):489-502.
31. Chen, JC, Chiu MH, Nie RL, Cordell GA and Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Natural Product Reports. 2005; 22(3):386-399.
32. Chan, KT, Meng FY, Li Q, Ho CY, Lam TS, To Y, Lee WH, Li M, Chu KH and Toh M. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Letters. 2010; 294(1):118-124.
33. Zhang, M, Sun C, Shan X, Yang X, Li-Ling J and Deng Y. Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas. 2010; 39(6):923-929.
34. Jin, HR, Jin X, Dat NT and Lee JJ. Cucurbitacin B suppresses the transactivation activity of RelA/p Journal of Cellular Biochemistry. 2011; 112(6):1643-1650.
35. Thoennissen, NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW and Koeffler HP. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Research. 2009; 69(14):5876-5884.
36. Duangmano, S, Dakeng S, Jiratchariyakul W, Suksamrarn A, Smith DR and Patmasiriwat P. Antiproliferative Effects of Cucurbitacin B in Breast Cancer Cells: Down-Regulation of the c-Myc/hTERT/Telomerase Pathway and Obstruction of the Cell Cycle. International Journal of Molecular Sciences. 2010; 11(12):5323-5338.
37. Pastorino, JG, Chen ST, Tafani M, Snyder JW and Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem. 1998; 273(13):7770-7775.
38. Wood, DE and Newcomb EW. Cleavage of Bax enhances its cell death function. Exp Cell Res. 2000; 256(2):375-382.
39. Toyota, H, Yanase N, Yoshimoto T, Moriyama M, Sudo T and Mizuguchi J. Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax. Cancer Lett. 2003; 189(2):221-230.
40. Janicke, RU, Sprengart ML, Wati MR and Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998; 273(16):9357-9360.
41. Wang, SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A and Arteaga CL. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Molecular and Cellular Biology. 2008; 28(18):5605-5620.
42. Nahta, R. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Current Medicinal Chemistry. 2012; 19(7):1065-1075.
43. Tannin-Spitz, T, Grossman S, Dovrat S, Gottlieb HE and Bergman M. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochemical Pharmacology. 2007; 73(1):56-67.
44. Promkan, M, Dakeng S, Chakrabarty S, Bogler O and Patmasiriwat P. The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells. PLoS One. 2013; 8(2):e55732.
45. Wakimoto, N, Yin D, O'Kelly J, Haritunians T, Karlan B, Said J, Xing H and Koeffler HP. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Science. 2008; 99(9):1793-1797.
46. Bao, L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R and Dash S. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. American Journal of Pathology. 2011; 178(2):838-852.
47. Biscardi, JS, Maa MC, Tice DA, Cox ME, Leu TH and Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. The Journal of Biological Chemistry. 1999; 274(12):8335-8343.
48. Bouton, AH, Riggins RB and Bruce-Staskal PJ. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene. 2001; 20(44):6448-6458.
49. Glukhova, MA and Streuli CH. How integrins control breast biology. Current Opinion in Cell Biology. 2013; 25(5):633-641.
50. Gerson, KD, Shearstone JR, Maddula VS, Seligmann BE and Mercurio AM. Integrin beta4 regulates SPARC protein to promote invasion. The Journal of Biological Chemistry. 2012; 287(13):9835-9844.
51. Draheim, KM, Chen HB, Tao Q, Moore N, Roche M and Lyle S. ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta Oncogene. 2010; 29(36):5032-5047.
52. Chen, M, Sinha M, Luxon BA, Bresnick AR and O'Connor KL. Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. The Journal of Biological Chemistry. 2009; 284(3):1484-1494.
53. Lu, S, Simin K, Khan A and Mercurio AM. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clinical Cancer Research. 2008; 14(4):1050-1058.
54. Lu, S, Simin K, Khan A and Mercurio AM. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res. 2008; 14(4):1050-1058.
55. Schwartz, MA. Integrins, oncogenes, and anchorage independence. J Cell Biol. 1997; 139(3):575-578.
56. Gilcrease, MZ. Integrin signaling in epithelial cells. Cancer Letters. 2007; 247(1):1-25.
57. Schaller, MD, Otey CA, Hildebrand JD and Parsons JT. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol. 1995; 130(5):1181-1187.
58. Hannigan, G, Troussard AA and Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nature Reviews Cancer. 2005; 5(1):51-63.
59. Zhang, Y, Ouyang D, Xu L, Ji Y, Zha Q, Cai J and He X. Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells. Acta Biochimica et Biophysica Sinica. 2011; 43(7):556-567.
60. Kausar, H, Munagala R, Bansal SS, Aqil F, Vadhanam MV and Gupta RC. Cucurbitacin B potently suppresses nonsmall-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Letters. 2013; 332(1):35-45.
61. Aribi, A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, Toh M, Said JW and Koeffler HP. The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. International Journal of Cancer. 2013; 132(12):2730-2737.
62. Tao, K, Fang M, Alroy J and Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008; 8:228.
63. Gupta, P and Srivastava SK. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Medicine. 2012; 10:80.
64. Gupta, P, Adkins C, Lockman P and Srivastava SK. Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel Metastasis Model. PLoS One. 2013; 8(6):e67278.
65. Sahu, RP, Zhang R, Batra S, Shi Y and Srivastava SK. Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis. 2009; 30(10):1744-1753.
66. Loganathan, S, Kandala PK, Gupta P and Srivastava SK. Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. PLoS One. 2012; 7(8):e43577.
67. Batra, S, Sahu RP, Kandala PK and Srivastava SK. Benzyl Isothiocyanate-Mediated Inhibition of Histone Deacetylase Leads to NF-{kappa}B Turnoff in Human Pancreatic Carcinoma Cells. Molecular Cancer Therapeutics. 2010.
68. Boreddy, SR, Pramanik KC and Srivastava SK. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clinical Cancer Research. 2011; 17(7):1784-1795.
69. Sahu, RP and Srivastava SK. The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. Journal of National Cancer Institute. 2009; 101(3):176-193.